Lung cancer combo therapy aims to clear tumors before surgery
NCT ID NCT07704645
First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time
Summary
This phase II trial investigates whether combining the immunotherapy adebelizumab with other anti-tumor drugs, given before and after surgery, can improve outcomes for people with resectable non-small cell lung cancer. The study enrolls adults aged 18-70 with stage II or IIIA disease who are candidates for curative surgery. The main goal is to see if the treatment leads to a complete disappearance of cancer cells in the removed tissue (pathological complete response).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- adebelizumab combined with other anti-tumor drugs
- What this could lead to
- If successful, this combination approach could improve the chances of eliminating all cancer before surgery and reduce the risk of recurrence in people with early-stage lung cancer.
- What could go wrong
- This is a phase II trial, so the combination's safety and effectiveness are not yet proven. Side effects from the drug combination could be significant, and the results may not lead to a new standard treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, 200000, China
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.